stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Net income
Zai Lab Limited Unsponsored ADR's net income for fiscal 2025 was −$175.5M, compared with −$257.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$198.4M. Over the past ten years it has ranged from −$704.5M (fiscal 2021) to −$18.0M (fiscal 2015); the current reading is higher than 64% of that period. Net income has risen for 4 consecutive fiscal years. Zai Lab Limited Unsponsored ADR ranks 518th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$175.5M | — |
| FY2024 | −$257.1M | — |
| FY2023 | −$334.6M | — |
| FY2022 | −$443.3M | — |
| FY2021 | −$704.5M | — |
| FY2020 | −$268.9M | — |
| FY2019 | −$195.1M | — |
| FY2018 | −$139.1M | — |
| FY2017 | −$50.4M | — |
| FY2016 | −$37.5M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$46.1M | — |
| Jun 2026 | −$50.8M | — |
| Mar 2026 | −$51.0M | — |
| Dec 2025 | −$50.4M | — |
| 32 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ADMA ADMA Biologics Inc compare | $182.4M |
| MBX MBX Biosciences, Inc. compare | −$104.3M |
| XNCR Xencor, Inc. compare | −$163.3M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| ZLAB Zai Lab Limited Unsponsored ADR | −$198.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| RCUS Arcus Biosciences, Inc. compare | −$453.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ZLAB
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement